| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3947 |
| Trial ID | NCT06503211 |
| Disease | B-Cell Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | UTAA09 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Clinical Study on the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Recurrent or Refractory B-cell Non Hodgkin's Lymphoma |
| Year | 2024 |
| Country | China |
| Company sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Other ID(s) | UCART-19-002 |
| Cohort 1 | |||||||||
|
|||||||||